HIKALHikal Ltd.

₹244.95-1.25%

Market Cap

₹3,059.09 Cr

Stock P/E

48.33

ROCE

9.88%

ROE

7.41%

Book Value

₹100.56

Financials

YoY Net Sales

EPS Growth

Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Institution

Public

Others

From Last Concall

POSITIVES

•
Regulatory credibility strengthened by successful GMP audits from ANVISA and PMDA at the Bangalore API facility.
•
Strong immediate cash generation with positive free cash flow in Q1 (Rs 15 crores) and improved working capital.

NEGATIVES

•
US FDA OAI status at Bangalore creates near-term regulatory risk and potential disruption to APIs.
•
Q1 revenue was deferred by about Rs 50 crores due to deferment of orders, pressuring near-term revenue recognition.

Peers Summary

Sector Laggard

Hikal Ltd. is underperforming relative to its peers in the Pharmaceuticals & Drugs sector, showing negative revenue growth and lower profitability metrics. Its valuation metrics also suggest it may be overvalued compared to its growth prospects, which are declining.

Key Points

• Hikal Ltd. has the lowest revenue growth YoY and lowest EPS among peers.
• The company exhibits lower ROE and ROA compared to its peers, indicating weaker profitability.
• Hikal's PE ratio is high relative to its growth, suggesting it may be overvalued.
• Key peers like Cipla and Dr. Reddy's show strong profitability and solid growth, making them attractive investment options.

Top Performers

Cipla Ltd.

Strong revenue growth and profitability metrics with attractive valuation ratios.

Dr. Reddy's Laboratories Ltd.

High ROE and ROA with very low PE ratio, indicating good value and strong business performance.

Mankind Pharma Ltd.

Exceptional revenue growth and solid profitability metrics, despite moderate valuation.

Explore

Watchlists

Command Palette